PFI & Formulations Development
The Gagillapur facility has one of the world’s largest single-site finished dosage capacities with automated processes,
robust infrastructure and superior quality systems that efficiently produce finished dosages, meeting stringent benchmarks in regulated markets. Our process development laboratory and pilot plant for R&D initiatives replicate our PFI and Finished Dosage operations on a smaller scale. This enables our team to work on R&D efforts, while reducing the interruption in commercial manufacturing areas.
We also recognize the importance of our client’s requirements to develop robust and compliant formulations. Best-in-class analytical methods, accelerated and real-time stability studies, along with a variety of stress stability are employed to deliver the best formulation for any product.
The team offers end-to-end product development solutions covering:
GPI, Granules’100% wholly-owned subsidiary in Chantilly, Virginia focuses on formulation R&D with emphasis on products with specific release properties, ODTs and DEA controlled substances. This helps us upgrade our product portfolio with value-added complex generics.